mCRC Clinical Studies
Three large RCTs are investigating the first-line use of SIR-Spheres® Y-90 resin microspheres in metastatic colorectal cancer (mCRC). Key endpoints from the SIRFLOX study were reported at the ASCO 2015 Annual Meeting and published in the Journal of Clinical Oncology in 2016. Overall Survival, the primary endpoint of the FOXFIRE and FOXFIRE Global studies which share a very similar study design to SIRFLOX, is expected in 2017. These data will be combined with the overall survival result from SIRFLOX, representing >1100 subjects, in a pre-planned combined analysis.
In addition to the SIRFLOX and FOXFIRE studies, other clinical studies are currently investigating the treatment of mCRC, HCC, and other unresectable liver tumours with SIR-Spheres Y-90 resin microspheres.
SIR-Spheres Y-90 resin microspheres have been extensively used in the treatment of liver metastases from colorectal cancer. Numerous studies, including randomised controlled trials, have been published on the combination of SIR-Spheres Y-90 resin microspheres with first-line chemotherapy, as well as in subsequent lines in combination with chemotherapy or as a single agent for mCRC. View summary of published data for SIR-Spheres Y-90 resin microspheres in the treatment of mCRC